miR-142-3p could prevent MDSC differentiation during tumor-induced myelopoiesis by modulating STAT3 and C/EBPβ signal pathway, indicating that the potential therapeutic application for miR-142-3p oligonucleotide as adjuvant tool for adoptive T cell therapy of cancer 28 (Figure 1). This evidence concerns the gene CEBPB and neoplasm.